Last mentioned: Mar 18, 2026
Expected Response
Deadline for CDSCO to justify the delay in regulatory action (Estimated).
Contempt Petition Filed
Petitioners allege CDSCO failed to act on the court's previous safety mandate.
Notice Issued
Justice Sachin Datta issues formal contempt notice seeking a response from the CDSCO.
Contempt Notice Issued
Justice Sachin Datta issues formal notice to CDSCO seeking an explanation for the delay.
Contempt Petition Filed
Petitioners allege CDSCO failed to act on the court's previous directions.
Contempt Notice Issued
Justice Sachin Datta seeks a formal response from CDSCO regarding the delay.
Original Court Order
Delhi HC directs CDSCO to examine safety and regulatory concerns of diabetes drugs used for weight management.
Contempt Petition Filed
Petitioners move court alleging CDSCO failed to meet the review deadline.
Initial Judicial Order
Delhi HC directs CDSCO to examine the safety of diabetes drugs used for weight management.
Initial Court Order
Delhi HC directs CDSCO to evaluate safety of diabetes drugs for weight loss.
The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to examine safety concerns regarding the off-label use of diabetes medications for weight loss. This judicial escalation highlights growing concerns over the unregulated boom of GLP-1 agonists in the Indian market.
The Delhi High Court has issued a contempt notice to India's drug regulator, CDSCO, for failing to comply with judicial orders to evaluate the safety of diabetes drugs used off-label for weight loss. This escalation signals a growing legal intolerance for regulatory delays amidst a global surge in GLP-1 receptor agonist demand.
The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to act on a judicial mandate to evaluate the safety of diabetes medications used off-label for weight loss. This escalation highlights growing judicial impatience with regulatory inertia regarding the global surge in GLP-1 receptor agonist use.